Showing results (271-280 of 316) with videos related to

Sort By:
Pageof 32
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 8, 2022
Prognostic value of plasma circulating tumor DNA fraction across four common cancer types: a real-world outcomes studyZ R Reichert, T M Morgan, G Li, et al.
Cancer Medicine|January 15, 2026
Emergence of BRCA Reversion Mutations in Prostate Cancer Prior to PARP Inhibitor Exposure: Clinical and Therapeutic ImplicationsDouglas I Lin, Elizabeth Lawrence, Natalie Danziger, et al.
Breast Cancer Research and Treatment|June 13, 2024
Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(-) metastatic breast cancer: prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practiceManali A Bhave, Julia C F Quintanilha, Hanna Tukachinsky, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|February 7, 2023
Mismatch repair deficiency, next-generation sequencing-based microsatellite instability, and tumor mutational burden as predictive biomarkers for immune checkpoint inhibitor effectiveness in frontline treatment of advanced stage endometrial cancerBreana L Hill, Ryon P Graf, Kunal Shah, et al.
JCO Precision Oncology|July 6, 2023
Tumor Mutational Burden in Real-World Patients With Pancreatic Cancer: Genomic Alterations and Predictive Value for Immune Checkpoint Inhibitor EffectivenessJulia C F Quintanilha, Michael H Storandt, Ryon P Graf, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 17, 2015
The Initial Detection and Partial Characterization of Circulating Tumor Cells in Neuroendocrine Prostate CancerHimisha Beltran, Adam Jendrisak, Mark Landers, et al.
ESMO Real World Data and Digital Oncology|February 6, 2026
Toward optimizing patient selection for EGFR antibody therapies in metastatic colorectal cancer: outcomes and resistance features in real-world dataM J Emmett, J C F Quintanilha, R P Graf, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 11, 2022
SPOP Mutations as a Predictive Biomarker for Androgen Receptor Axis-Targeted Therapy in De Novo Metastatic Castration-Sensitive Prostate CancerUmang Swami, Ryon P Graf, Roberto H Nussenzveig, et al.
JAMA Network Open|January 23, 2023
Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy in Patients With Metastatic Colorectal Cancer With Measures of Microsatellite Instability, Mismatch Repair, or Tumor Mutational BurdenJulia C F Quintanilha, Ryon P Graf, Virginia A Fisher, et al.
JAMA Oncology|June 30, 2018
Assessment of the Validity of Nuclear-Localized Androgen Receptor Splice Variant 7 in Circulating Tumor Cells as a Predictive Biomarker for Castration-Resistant Prostate CancerHoward I Scher, Ryon P Graf, Nicole A Schreiber, et al.
Pageof 32